Common gamma chain cytokines in combinatorial immune strategies against cancer

Immunology Letters

Volumn 169, Issue , 2016, Pages 61-72

  Pulliam, Stephanie R ^a   Uzhachenko, Roman V ^a   Adunyah, Samuel E ^a   Shanker, Anil ^a,b  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Cancer immunotherapy; Gamma chain cytokines; Hematopoietic malignancies; Immunostimulation; Solid cancers

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; CYTOKINE; INTERLEUKIN 2 RECEPTOR GAMMA;

CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; DRUG EFFICACY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOSTIMULATION; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT PLANNING; ANIMAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CYTOKINES; HUMANS; IMMUNOTHERAPY; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; LYMPHOCYTES; NEOPLASMS;

EID: 84949024607     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.11.007     Document Type: Review

References (162)

1. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 2004, 4:11-22.
2. Huang W.H., Chang M.C., Tsai K.S., Hung M.C., Chen H.L., Hung S.C. Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Oncogene 2013, 32:4343-4354.
3. McAllister S.S., Weinberg R.A. Tumor-host interactions: a far-reaching relationship. J. Clin. Oncol. 2010, 28:4022-4028.
4. Chow M.T., Luster A.D. Chemokines in cancer. Cancer Immunol. Res. 2014, 2:1125-1131.
5. Ramanathan S., Jagannathan N. Tumor associated macrophage: a review on the phenotypes, traits and functions. Iran. J. Cancer Prev. 2014, 7:1-8.
6. Landskron G., De la Fuente M., Thuwajit P., Thuwajit C., Hermoso M.A. Chronic inflammation and cytokines in the tumor microenvironment. J. Immunol. Res. 2014, 2014. 149185.
7. Li Z., Chen L., Qin Z. Paradoxical roles of IL-4 in tumor immunity. Cell. Mol. Immunol. 2009, 6:415-422.
8. Overwijk W.W., Schluns K.S. Functions of gammaC cytokines in immune homeostasis: current and potential clinical applications. Clin. Immunol. 2009, 132:153-165.
9. Schmitt E., Bopp T. Amazing IL-9: revealing a new function for an old cytokine. J. Clin. Investig. 2012, 122:3857-3859.
10. Fewkes N.M., Mackall C.L. Novel gamma-chain cytokines as candidate immune modulators in immune therapies for cancer. Cancer J. 2010, 16:392-398.
11. Meazza R., Azzarone B., Orengo A.M., Ferrini S. Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J. Biomed. Biotechnol. 2011, 2011. 861920.
12. Sim G.C., Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 2014, 25:377-390.
13. Boyman O., Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat. Rev. Immunol. 2012, 12:180-190.
14. Morgan D.A., Ruscetti F.W., Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976, 193:1007-1008.
15. Mingari M.C., Gerosa F., Carra G., Accolla R.S., Moretta A., Zubler R.H., et al. Human interleukin-2 promotes proliferation of activated B cells via surface receptors similar to those of activated T cells. Nature 1984, 312:641-643.
16. Siegel J.P., Sharon M., Smith P.L., Leonard W.J. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science 1987, 238:75-78.
17. Cote-Sierra J., Foucras G., Guo L., Chiodetti L., Young H.A., Hu-Li J., et al. Interleukin 2 plays a central role in Th2 differentiation. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3880-3885.
18. Liao W., Schones D.E., Oh J., Cui Y., Cui K., Roh T.Y., et al. Priming for T helper type 2 differentiation by interleukin 2-mediated induction of interleukin 4 receptor alpha-chain expression. Nat. Immunol. 2008, 9:1288-1296.
19. Refaeli Y., Van Parijs L., London C.A., Tschopp J., Abbas A.K. Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis. Immunity 1998, 8:615-623.
20. Jain J., Loh C., Rao A. Transcriptional regulation of the IL-2 gene. Curr. Opin. Immunol. 1995, 7:333-342.
21. Itoh M., Takahashi T., Sakaguchi N., Kuniyasu Y., Shimizu J., Otsuka F., et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J. Immunol. 1999, 162:5317-5326.
22. Corthay A. How do regulatory T cells work?. Scand. J. Immunol. 2009, 70:326-336.
23. Takeshita T., Asao H., Ohtani K., Ishii N., Kumaki S., Tanaka N., et al. Cloning of the gamma chain of the human IL-2 receptor. Science 1992, 257:379-382.
24. Russell S.M., Johnston J.A., Noguchi M., Kawamura M., Bacon C.M., Friedmann M., et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 1994, 266:1042-1045.
25. Gaffen S.L., Lai S.Y., Xu W., Gouilleux F., Groner B., Goldsmith M.A., et al. Signaling through the interleukin 2 receptor beta chain activates a STAT-5-like DNA-binding activity. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7192-7196.
26. Merida I., Diez E., Gaulton G.N. IL-2 binding activates a tyrosine-phosphorylated phosphatidylinositol-3-kinase. J. Immunol. 1991, 147:2202-2207.
27. Karnitz L.M., Sutor S.L., Abraham R.T. The Src-family kinase, Fyn, regulates the activation of phosphatidylinositol 3-kinase in an interleukin 2-responsive T cell line. J. Exp. Med. 1994, 179:1799-1808.
28. Delespine-Carmagnat M., Bouvier G., Bertoglio J. Association of STAT1, STAT3 and STAT5 proteins with the IL-2 receptor involves different subdomains of the IL-2 receptor beta chain. Eur. J. Immunol. 2000, 30:59-68.
29. Burchill M.A., Yang J., Vogtenhuber C., Blazar B.R., Farrar M.A. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J. Immunol. 2007, 178:280-290.
30. Lin J.X., Li P., Liu D., Jin H.T., He J., Ata Ur Rasheed M., et al. Critical Role of STAT5 transcription factor tetramerization for cytokine responses and normal immune function. Immunity 2012, 36:586-599.
31. Yang X.P., Ghoreschi K., Steward-Tharp S.M., Rodriguez-Canales J., Zhu J., Grainger J.R., et al. Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat. Immunol. 2011, 12:247-254.
32. Sadlack B., Merz H., Schorle H., Schimpl A., Feller A.C., Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75:253-261.
33. Sharfe N., Dadi H.K., Shahar M., Roifman C.M. Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:3168-3171.
34. Noguchi M., Yi H., Rosenblatt H.M., Filipovich A.H., Adelstein S., Modi W.S., et al. Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 1993, 73:147-157.
35. Reichert T.E., Nagashima S., Kashii Y., Stanson J., Gao G., Dou Q.P., et al. Interleukin-2 expression in human carcinoma cell lines and its role in cell cycle progression. Oncogene 2000, 19:514-525.
36. Bhatia S.K., Tygrett L.T., Grabstein K.H., Waldschmidt T.J. The effect of in vivo IL-7 deprivation on T cell maturation. J. Exp. Med. 1995, 181:1399-1409.
37. Tan J.T., Dudl E., LeRoy E., Murray R., Sprent J., Weinberg K.I., et al. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8732-8737.
38. Namen A.E., Lupton S., Hjerrild K., Wignall J., Mochizuki D.Y., Schmierer A., et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1988, 333:571-573.
39. Opferman J.T., Letai A., Beard C., Sorcinelli M.D., Ong C.C., Korsmeyer S.J. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003, 426:671-676.
40. Rathmell J.C., Farkash E.A., Gao W., Thompson C.B. IL-7 enhances the survival and maintains the size of naive T cells. J. Immunol. 2001, 167:6869-6876.
41. Hara T., Shitara S., Imai K., Miyachi H., Kitano S., Yao H., et al. Identification of IL-7-producing cells in primary and secondary lymphoid organs using IL-7-GFP knock-in mice. J. Immunol. 2012, 189:1577-1584.
42. Maeurer M.J., Walter W., Martin D., Zitvogel L., Elder E., Storkus W., et al. Interleukin-7 (IL-7) in colorectal cancer: IL-7 is produced by tissues from colorectal cancer and promotes preferential expansion of tumour infiltrating lymphocytes. Scand. J. Immunol. 1997, 45:182-192.
43. Cosenza L., Gorgun G., Urbano A., Foss F. Interleukin-7 receptor expression and activation in nonhaematopoietic neoplastic cell lines. Cell. Signal. 2002, 14:317-325.
44. Page T.H., Lali F.V., Foxwell B.M. Interleukin-7 activates p56lck and p59fyn, two tyrosine kinases associated with the p90 interleukin-7 receptor in primary human T cells. Eur. J. Immunol. 1995, 25:2956-2960.
45. Sharfe N., Dadi H.K., Roifman C.M. JAK3 protein tyrosine kinase mediates interleukin-7-induced activation of phosphatidylinositol-3' kinase. Blood 1995, 86:2077-2085.
46. Foxwell B.M., Beadling C., Guschin D., Kerr I., Cantrell D. Interleukin-7 can induce the activation of Jak 1, Jak 3 and STAT 5 proteins in murine T cells. Eur. J. Immunol. 1995, 25:3041-3046.
47. Zhang Y., Pfannenstiel L.W., Bolesta E., Montes C.L., Zhang X., Chapoval A.I., et al. Interleukin-7 inhibits tumor-induced CD27-CD28- suppressor T cells: implications for cancer immunotherapy. Clin. Cancer Res. 2011, 17:4975-4986.
48. Fry T.J., Connick E., Falloon J., Lederman M.M., Liewehr D.J., Spritzler J., et al. A potential role for interleukin-7 in T-cell homeostasis. Blood 2001, 97:2983-2990.
49. Puel A., Ziegler S.F., Buckley R.H., Leonard W.J. Defective IL7R expression in T(-)B(+)NK(+) severe combined immunodeficiency. Nat. Genet. 1998, 20:394-397.
50. Burton J.D., Bamford R.N., Peters C., Grant A.J., Kurys G., Goldman C.K., et al. A lymphokine, provisionally designated interleukin T and produced by a human adult T-cell leukemia line, stimulates T-cell proliferation and the induction of lymphokine-activated killer cells. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:4935-4939.
51. Grabstein K.H., Eisenman J., Shanebeck K., Rauch C., Srinivasan S., Fung V., et al. Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor. Science 1994, 264:965-968.
52. Kennedy M.K., Glaccum M., Brown S.N., Butz E.A., Viney J.L., Embers M., et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 2000, 191:771-780.
53. Ranson T., Vosshenrich C.A., Corcuff E., Richard O., Laloux V., Lehuen A., et al. IL-15 availability conditions homeostasis of peripheral natural killer T cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2663-2668.
54. Carson W.E., Fehniger T.A., Haldar S., Eckhert K., Lindemann M.J., Lai C.F., et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J. Clin. Investig. 1997, 99:937-943.
55. Shenoy A.R., Kirschnek S., Hacker G. IL-15 regulates Bcl-2 family members Bim and Mcl-1 through JAK/STAT and PI3K/AKT pathways in T cells. Eur. J. Immunol. 2014, 44:2500-2507.
56. Berard M., Brandt K., Bulfone-Paus S., Tough D.F. IL-15 promotes the survival of naive and memory phenotype CD8+ T cells. J. Immunol. 2003, 170:5018-5026.
57. Yamane H., Paul W.E. Cytokines of the gamma(c) family control CD4+ T cell differentiation and function. Nat. Immunol. 2012, 13:1037-1044.
58. Giri J.G., Ahdieh M., Eisenman J., Shanebeck K., Grabstein K., Kumaki S., et al. Utilization of the beta and gamma chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 1994, 13:2822-2830.
59. Giri J.G., Kumaki S., Ahdieh M., Friend D.J., Loomis A., Shanebeck K., et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the alpha chain of the IL-2 receptor. EMBO J. 1995, 14:3654-3663.
60. Dubois S., Mariner J., Waldmann T.A., Tagaya Y. IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells. Immunity 2002, 17:537-547.
61. Burkett P.R., Koka R., Chien M., Chai S., Boone D.L., Ma A. Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis. J. Exp. Med. 2004, 200:825-834.
62. Waldmann T.A. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 2006, 6:595-601.
63. Leclercq G., Debacker V., de Smedt M., Plum J. Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells. J. Exp. Med. 1996, 184:325-336.
64. Arneja A., Johnson H., Gabrovsek L., Lauffenburger D.A., White F.M. Qualitatively different T cell phenotypic responses to IL-2 versus IL-15 are unified by identical dependences on receptor signal strength and duration. J. Immunol. 2014, 192:123-135.
65. Onu A., Pohl T., Krause H., Bulfone-Paus S. Regulation of IL-15 secretion via the leader peptide of two IL-15 isoforms. J. Immunol. 1997, 158:255-262.
66. Parrish-Novak J., Dillon S.R., Nelson A., Hammond A., Sprecher C., Gross J.A., et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000, 408:57-63.
67. Spolski R., Leonard W.J. Interleukin-21: a double-edged sword with therapeutic potential. Nat. Rev. Drug Discov. 2014, 13:379-395.
68. Wei L., Laurence A., Elias K.M., O'Shea J.J. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J. Biol. Chem. 2007, 282:34605-34610.
69. Hong C., Luckey M.A., Ligons D.L., Waickman A.T., Park J.Y., Kim G.Y., et al.Activated T. cells secrete an alternatively spliced form of common gamma-chain that inhibits cytokine signaling and exacerbates inflammation. Immunity 2014, 40:910-923.
70. Wan C.K., Oh J., Li P., West E.E., Wong E.A., Andraski A.B., et al. The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity 2013, 38:514-527.
71. Kim H.P., Korn L.L., Gamero A.M., Leonard W.J. Calcium-dependent activation of interleukin-21 gene expression in T cells. J. Biol. Chem. 2005, 280:25291-25297.
72. Pandey A., Ozaki K., Baumann H., Levin S.D., Puel A., Farr A.G., et al. Cloning of a receptor subunit required for signaling by thymic stromal lymphopoietin. Nat. Immunol. 2000, 1:59-64.
73. Habib T., Senadheera S., Weinberg K., Kaushansky K. The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry 2002, 41:8725-8731.
74. Zeng R., Spolski R., Casas E., Zhu W., Levy D.E., Leonard W.J. The molecular basis of IL-21-mediated proliferation. Blood 2007, 109:4135-4142.
75. Fuqua C.F., Akomeah R., Price J.O., Adunyah S.E. Involvement of ERK-1/2 in IL-21-induced cytokine production in leukemia cells and human monocytes. Cytokine 2008, 44:101-107.
76. Kwon H., Thierry-Mieg D., Thierry-Mieg J., Kim H.P., Oh J., Tunyaplin C., et al. Analysis of interleukin-21-induced Prdm1 gene regulation reveals functional cooperation of STAT3 and IRF4 transcription factors. Immunity 2009, 31:941-952.
77. Miki K., Nagaoka K., Harada M., Hayashi T., Jinguji H., Kato Y., et al. Combination therapy with dendritic cell vaccine and IL-2 encapsulating polymeric micelles enhances intra-tumoral accumulation of antigen-specific CTLs. Int. Immunopharmacol. 2014, 23:499-504.
78. Levin A.M., Bates D.L., Ring A.M., Krieg C., Lin J.T., Su L., et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 2012, 484:529-533.
79. Mitra S., Ring A.M., Amarnath S., Spangler J.B., Li P., Ju W., et al. Interleukin-2 activity can be fine tuned with engineered receptor signaling clamps. Immunity 2015, 42:826-838.
80. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Ettinghausen S.E., et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 1985, 313:1485-1492.
81. Rosenberg S.A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 2014, 192:5451-5458.
82. Yang J.C., Sherry R.M., Steinberg S.M., Topalian S.L., Schwartzentruber D.J., Hwu P., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 2003, 21:3127-3132.
83. Sun M., Lughezzani G., Perrotte P., Karakiewicz P.I. Treatment of metastatic renal cell carcinoma. Nat. Rev. Urol. 2010, 7:327-338.
84. Coppin C., Porzsolt F., Awa A., Kumpf J., Coldman A., Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 2005, CD001425.
85. Rosenberg S.A., Yannelli J.R., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. 1994, 86:1159-1166.
86. Thakur A., Lum L.G., Al-Kadhimi Z., Colvin G.A., Cummings F.J., Legare R.D., et al.Targeted T. cell Therapy in Stage IV Breast Cancer: a Phase I Clinical Trial. Clin. Cancer Res. 2015, 21:2304-2314.
87. Catania C., Maur M., Berardi R., Rocca A., Giacomo A.M., Spitaleri G., et al. The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer. Cell Adhes. Migr. 2015, 9:14-21.
88. Marlind J., Kaspar M., Trachsel E., Sommavilla R., Hindle S., Bacci C., et al. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin. Cancer Res. 2008, 14:6515-6524.
89. Midwood K.S., Hussenet T., Langlois B., Orend G. Advances in tenascin-C biology. Cell. Mol. Life Sci. 2011, 68:3175-3199.
90. Lee J.H., Lee J.H., Lim Y.S., Yeon J.E., Song T.J., Yu S.J., et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015, 148:1383-1391.e6. e1386.
91. Pievani A., Borleri G., Pende D., Moretta L., Rambaldi A., Golay J., et al. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011, 118:3301-3310.
92. Yuan C.H., Yang X.Q., Zhu C.L., Liu S.P., Wang B.C., Wang F.B. Interleukin-7 enhances the in vivo anti-tumor activity of tumor-reactive CD8+ T cells with induction of IFN-gamma in a murine breast cancer model. Asian Pac. J. Cancer Prev. 2014, 15:265-271.
93. Fritzell S., Eberstal S., Sanden E., Visse E., Darabi A., Siesjo P. IFNgamma in combination with IL-7 enhances immunotherapy in two rat glioma models. J. Neuroimmunol. 2013, 258:91-95.
94. Gou H.F., Huang J., Shi H.S., Chen X.C., Wang Y.S. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice. PloS One 2014, 9:e85789.
95. Berger C., Berger M., Hackman R.C., Gough M., Elliott C., Jensen M.C., et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009, 114:2417-2426.
96. Yu P., Steel J.C., Zhang M., Morris J.C., Waldmann T.A. Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model. Clin. Cancer Res. 2010, 16:6019-6028.
97. Ming J., Jiang G., Zhang Q., Qiu X., Wang E. Interleukin-7 up-regulates cyclin D1 via activator protein-1 to promote proliferation of cell in lung cancer. Cancer Immunol. Immunother. 2012, 61:79-88.
98. Gattinoni L., Finkelstein S.E., Klebanoff C.A., Antony P.A., Palmer D.C., Spiess P.J., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005, 202:907-912.
99. Dudley M.E., Wunderlich J.R., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 2002, 25:243-251.
100. Ochoa M.C., Fioravanti J., Rodriguez I., Hervas-Stubbs S., Azpilikueta A., Mazzolini G., et al. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. Cancer Res. 2013, 73:139-149.
101. Kermer V., Hornig N., Harder M., Bondarieva A., Kontermann R.E., Muller D. Combining antibody-directed presentation of IL-15 and 4-1BBL in a trifunctional fusion protein for cancer immunotherapy. Mol. Cancer Ther. 2014, 13:112-121.
102. Rosenberg S.A., Sportes C., Ahmadzadeh M., Fry T.J., Ngo L.T., Schwarz S.L., et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother. 2006, 29:313-319.
103. Sportes C., Babb R.R., Krumlauf M.C., Hakim F.T., Steinberg S.M., Chow C.K., et al.Phase I. study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin. Cancer Res. 2010, 16:727-735.
104. Conlon K.C., Lugli E., Welles H.C., Rosenberg S.A., Fojo A.T., Morris J.C., et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 2015, 33:74-82.
105. Mengus C., Le Magnen C., Trella E., Yousef K., Bubendorf L., Provenzano M., et al. Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J. Transl. Med. 2011, 9:162.
106. Wang G., Tschoi M., Spolski R., Lou Y., Ozaki K., Feng C., et al. In vivo antitumor activity of interleukin 21 mediated by natural killer cells. Cancer Res. 2003, 63:9016-9022.
107. Petersen C.C., Diernaes J.E., Skovbo A., Hvid M., Deleuran B., Hokland M. Interleukin-21 restrains tumor growth and induces a substantial increase in the number of circulating tumor-specific T cells in a murine model of malignant melanoma. Cytokine 2010, 49:80-88.
108. Kastirr I., Maglie S., Paroni M., Alfen J.S., Nizzoli G., Sugliano E., et al. IL-21 is a central memory T cell-associated cytokine that inhibits the generation of pathogenic Th1/17 effector cells. J. Immunol. 2014, 193:3322-3331.
109. Wang Y., Chen J., Tang B., Zhang X., Hua Z.C. Systemic administration of attenuated in combination with interleukin-21 for cancer therapy. Mol. Clin. Oncol. 2013, 1:461-465.
110. Zoon C.K., Wan W., Graham L., Bear H.D. Addition of interleukin-21 for expansion of T-cells for adoptive immunotherapy of murine melanoma. Int. J. Mol. Sci. 2015, 16:8744-8760.
111. Battaglia A., Buzzonetti A., Baranello C., Fanelli M., Fossati M., Catzola V., et al. Interleukin-21 (IL-21) synergizes with IL-2 to enhance T-cell receptor-induced human T-cell proliferation and counteracts IL-2/transforming growth factor-beta-induced regulatory T-cell development. Immunology 2013, 139:109-120.
112. Attridge K., Wang C.J., Wardzinski L., Kenefeck R., Chamberlain J.L., Manzotti C., et al. IL-21 inhibits T cell IL-2 production and impairs Treg homeostasis. Blood 2012, 119:4656-4664.
113. He H., Wisner P., Yang G., Hu H.M., Haley D., Miller W., et al. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J. Transl. Med. 2006, 4:24.
114. Thompson J.A., Curti B.D., Redman B.G., Bhatia S., Weber J.S., Agarwala S.S., et al.Phase I. study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J. Clin. Oncol. 2008, 26:2034-2039.
115. Stolfi C., Rizzo A., Franze E., Rotondi A., Fantini M.C., Sarra M., et al. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer. J. Exp. Med. 2011, 208:2279-2290.
116. Bhatia S., Curti B., Ernstoff M.S., Gordon M., Heath E.I., Miller W.H., et al. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J. ImmunoTher. Cancer 2014, 2:2.
117. Coquet J.M., Skak K., Davis I.D., Smyth M.J., Godfrey D.I. IL-21 modulates activation of NKT cells in patients with stage IV malignant melanoma. Clin. Transl. Immunol. 2013, 2:e6.
118. Schliemann C., Gutbrodt K.L., Kerkhoff A., Pohlen M., Wiebe S., Silling G., et al. Targeting interleukin-2 to the bone marrow stroma for therapy of acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Cancer Immunol. Res. 2015, 3:547-556.
119. Buyse M., Squifflet P., Lange B.J., Alonzo T.A., Larson R.A., Kolitz J.E., et al. Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. Blood 2011, 117:7007-7013.
120. J.M. Horacek, T. Kupsa, M. Vasatova, L. Jebavy, P. Zak, Serum cytokine and adhesion molecule profile differs in newly diagnosed acute myeloid and lymphoblastic leukemia. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. 159 (2014) 299-301.
121. Terwijn M., Feller N., van Rhenen A., Kelder A., Westra G., Zweegman S., et al. Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. Eur. J. Cancer 2009, 45:1692-1699.
122. Gonen M., Sun Z., Figueroa M.E., Patel J.P., Abdel-Wahab O., Racevskis J., et al. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood 2012, 120:2297-2306.
123. Gaikwad A.S., Donohue R.E., Elghetany M.T., Sheehan A.M., Lu X.Y., Gramatges M.M., et al. Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia. Int. J. Clin. Exp. Pathol. 2014, 7:6225-6230.
124. E. Paietta, J. Racevskis, D. Neuberg, J.M. Rowe, A.H. Goldstone, P.H. Wiernik. Expression of CD25 (interleukin-2 receptor alpha chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC Intergroup Study E2993. Eastern Cooperative Oncology Group/Medical Research Council. Leukemia. 11 (1997) 1887-1890.
125. Nakase K., Kita K., Miwa H., Nishii K., Shikami M., Tanaka I., et al. Clinical and prognostic significance of cytokine receptor expression in adult acute lymphoblastic leukemia: interleukin-2 receptor alpha-chain predicts a poor prognosis. Leukemia 2007, 21:326-332.
126. Berkowitz J.L., Janik J.E., Stewart D.M., Jaffe E.S., Stetler-Stevenson M., Shih J.H., et al. Safety, efficacy, and pharmacokinetics/pharmacodynamics of daclizumab (anti-CD25) in patients with adult T-cell leukemia/lymphoma. Clin. Immunol. 2014, 155:176-187.
127. Mussai F., De Santo C., Abu-Dayyeh I., Booth S., Quek L., McEwen-Smith R.M., et al. Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment. Blood 2013, 122:749-758.
128. Buggins A.G., Milojkovic D., Arno M.J., Lea N.C., Mufti G.J., Thomas N.S., et al. Microenvironment produced by acute myeloid leukemia cells prevents T cell activation and proliferation by inhibition of NF-kappaB, c-Myc, and pRb pathways. J. Immunol. 2001, 167:6021-6030.
129. Silva A., Laranjeira A.B., Martins L.R., Cardoso B.A., Demengeot J., Yunes J.A., et al. IL-7 contributes to the progression of human T-cell acute lymphoblastic leukemias. Cancer Res. 2011, 71:4780-4789.
130. Shochat C., Tal N., Bandapalli O.R., Palmi C., Ganmore I., te Kronnie G., et al. Gain-of-function mutations in interleukin-7 receptor-alpha (IL7R) in childhood acute lymphoblastic leukemias. J. Exp. Med. 2011, 208:901-908.
131. Rozovski U., Li P., Harris D., Ohanian M., Kantarjian H., Estrov Z. Interleukin-7 receptor-alpha gene mutations are not detected in adult T-cell acute lymphoblastic leukemia. Cancer Med. 2014, 3:550-554.
132. Mansour M.R., Reed C., Eisenberg A.R., Tseng J.C., Twizere J.C., Daakour S., et al. Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. Br. J. Haematol. 2015, 168:230-238.
133. Brown V.I., Hulitt J., Fish J., Sheen C., Bruno M., Xu Q., et al. Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. Cancer Res. 2007, 67:9963-9970.
134. Sato N., Sabzevari H., Fu S., Ju W., Petrus M.N., Bamford R.N., et al. Development of an IL-15-autocrine CD8 T-cell leukemia in IL-15-transgenic mice requires the cis expression of IL-15Ralpha. Blood 2011, 117:4032-4040.
135. Steel J.C., Waldmann T.A., Morris J.C. Interleukin-15 biology and its therapeutic implications in cancer. Trends Pharmacol. Sci. 2012, 33:35-41.
136. Tao Q., Chen T., Tao L., Wang H., Pan Y., Xiong S., et al. IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+ cells and downregulating regulatory T cells as well as IL-35. J. Immunother. 2013, 36:462-467.
137. Roberts A.I., Lee L., Schwarz E., Groh V., Spies T., Ebert E.C., et al. NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J. Immunol. 2001, 167:5527-5530.
138. Zhou Z., Zhang C., Zhang J., Tian Z. Macrophages help NK cells to attack tumor cells by stimulatory NKG2D ligand but protect themselves from NK killing by inhibitory ligand Qa-1. PloS One 2012, 7:e36928.
139. Bug G., Ottmann O.G., The D.A.C. system and associations with acute leukemias and myelodysplastic syndromes. Investig. New Drugs 2010, 28(Suppl 1):S36-49.
140. Bi G., Jiang G. The molecular mechanism of HDAC inhibitors in anticancer effects. Cell. Mol. Immunol. 2006, 3:285-290.
141. Zdrenghea M.T. Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?. Med. Hypotheses 2013, 81:311-315.
142. Waldmann T.A., Conlon K.C., Stewart D.M., Worthy T.A., Janik J.E., Fleisher T.A., et al. Phase 1 trial of IL-15 trans presentation blockade using humanized Mikbeta1 mAb in patients with T-cell large granular lymphocytic leukemia. Blood 2013, 121:476-484.
143. Moga E., Canto E., Vidal S., Juarez C., Sierra J., Briones J. Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression. Exp. Hematol. 2011, 39:1064-1071.
144. Gowda A., Roda J., Hussain S.R., Ramanunni A., Joshi T., Schmidt S., et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood 2008, 111:4723-4730.
145. Jahrsdorfer B., Blackwell S.E., Wooldridge J.E., Huang J., Andreski M.W., Jacobus L.S., et al. B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 2006, 108:2712-2719.
146. Ahearne M.J., Willimott S., Pinon L., Kennedy D.B., Miall F., Dyer M.J., et al. Enhancement of CD154/IL4 proliferation by the T follicular helper (Tfh) cytokine, IL21 and increased numbers of circulating cells resembling Tfh cells in chronic lymphocytic leukaemia. Br. J. Haematol. 2013, 162:360-370.
147. Zeng R., Spolski R., Finkelstein S.E., Oh S., Kovanen P.E., Hinrichs C.S., et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 2005, 201:139-148.
148. Strengell M., Matikainen S., Siren J., Lehtonen A., Foster D., Julkunen I., et al. IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J. Immunol. 2003, 170:5464-5469.
149. Kishida T., Asada H., Itokawa Y., Cui F.D., Shin-Ya M., Gojo S., et al. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol. Ther. 2003, 8:552-558.
150. Pascutti M.F., Jak M., Tromp J.M., Derks I.A., Remmerswaal E.B., Thijssen R., et al. IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells. Blood 2013, 122:3010-3019.
151. Sun Y.X., Kong H.L., Liu C.F., Yu S., Tian T., Ma D.X., et al. The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia. Hum. Immunol. 2014, 75:113-118.
152. Timmerman J.M., Byrd J.C., Andorsky D.J., Yamada R.E., Kramer J., Muthusamy N., et al. A phase I dose-finding trial of recombinant interleukin-21 and rituximab in relapsed and refractory low grade B-cell lymphoproliferative disorders. Clin. Cancer Res. 2012, 18:5752-5760.
153. Rosenberg S.A., Lotze M.T., Muul L.M., Leitman S., Chang A.E., Vetto J.T., et al. A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. Surgery 1986, 100:262-272.
154. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 1995, 13:688-696.
155. Ridolfi L., Bertetto O., Santo A., Naglieri E., Lopez M., Recchia F., et al. Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial. Int. J. Oncol. 2011, 39:1011-1017.
156. Rosenberg S.A., Yang J.C., White D.E., Steinberg S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response. Ann. Surg. 1998, 228:307-319.
157. Kostner A.H., Ellegaard M.B., Christensen I.J., Bastholt L., Schmidt H. Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma. Cancer Immunol. Immunother. 2014, 64:349-355.
158. Petrella T.M., Tozer R., Belanger K., Savage K.J., Wong R., Smylie M., et al. Interleukin-21 has activity in patients with metastatic melanoma: a phase II study. J. Clin. Oncol. 2012, 30:3396-3401.
159. Stolfi C., Pallone F., Macdonald T.T., Monteleone G. Interleukin-2 in cancer immunotherapy: friend or foe?. Oncoimmunology 2012, 1:351-354.
160. Vandergeeten C. Fromentin R, DaFonseca S, Lawani MB, Sereti I, Lederman MM, et al: Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 2013, 121:4321-4329.
161. Managlia E.Z., Landay A., Al-Harthi L. Interleukin-7 induces HIV replication in primary naive T cells through a nuclear factor of activated T cell (NFAT)-dependent pathway. Virology 2006, 350:443-452.
162. Sereti I., Dunham R.M., Spritzler J., Aga E., Proschan M.A., Medvik K., et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009, 113:6304-6314.